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SPECIAL E D I T O R I A L 
A N N O U N C E M E N T 
Distribution and Transfer of Cyclosporine Among the 
Various Human Lipoprotein Classes 
W. Mraz, R. A. Zink, A. Graf, D. Preis, W. D. Miner, W. Land, W. Siebert, and H. Zöttlein 
CYCLOSPORINE-A (CsA) is a fungal cyclic oligopeptide with an immunosup-
pressive action in different animal species as 
well as in man.1 Since this molecule exhibits a 
strong hydrophobicity,2 , 3 it may be supposed 
that CsA is mainly associated with proteins in 
blood serum. 
In this article, evidence is presented for the 
exclusive association of CsA with lipoproteins 
in serum from renal transplant patients. Fur-
thermore, it could be demonstrated in vitro 
that there is an exchange/transfer of CsA 
among the different serum lipoprotein classes 
and a transfer of the compound from nonlipo-
protein proteins to lipoproteins. The physio-
logic implications of these findings are dis-
cussed. 
MATERIALS AND METHODS 
Sources of Blood Serum and Plasma 
Blood plasma samples for the preparative isolation of 
lipoproteins were obtained from normolipidemic volun-
teers (Blood bank, Klinikum Grosshadern, University of 
Munich). For the CsA distribution studies, blood was 
obtained from renal transplant patients receiving an oral 
dose of 12-17 mg/kg of body weight of the drug.4 The 
time interval between administration of CsA and blood 
sampling was 10 hr, unless otherwise stated. Patients who 
had fasted 8-i 5 hr were sampled. 
Chemicals 
Agar, bovine, and human serum albumin and antisera 
to apolipoprotein A and B were obtained from Behring-
werke (Marburg, F .R.G. ) ; antisera to apolipoproteins 
A-I , A-II , and B from Immuno Diagnostica (Heidelberg, 
F .R.G. ) . Metrizamide was purchased from Nyegaard 
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(Oslo, Norway); the scintillation solution Pico-Fluor 30 
and tritiated water as internal standard was obtained 
from Packard Instruments (Frankfurt, F .R .G. ) . All other 
chemicals were of reagent grade and were obtained from 
Merck (Darmstadt, F .R.G. ) . 
CsA and 3H-dihydro-CsA were gifts of Dr. R. Voges, 
and the CsA radioimmunoassay kit was provided by Dr. 
E . Abisch, both from Pharmaceutical Division, Sandoz 
Ltd. (Basel, Switzerland). 
Analytical Methods 
Total cholesterol, triglycerides, and choline-containing 
phospholipids in serum and ultracentrifugal fractions 
were determined enzymatically by standard methods,5"8 
using an automatic analyzer (Hitachi, model 705). Total 
protein was measured according to the method of Lowry 
et al., 9 using bovine serum albumin as a standard. 
Quantitative determination of the main lipoprotein 
fractions was performed by measuring their cholesterol 
contents after separation by semimicro-ultracentrifuga-
tion (Airfuge, Inc., Beckman Instruments, Palo Alto, 
C A ) at densities of 1.006 and 1.063 g/ml for very low 
density lipoprotein ( V L D L ) and high density lipoprotein 
( H D L ) , respectively. Low density lipoprotein ( L D L ) was 
calculated from the values of total, V L D L , and H D L 
cholesterol. The required densities were adjusted accord-
ing to Havel et a l . 1 0 
Agarose-gel electrophoresis11 was used for the qualita-
tive analysis of serum lipoprotein distribution as well as 
for the establishment of the purity of isolated lipoprotein 
fractions. 
To evaluate the serum protein and serum apolipopro-
tein distribution after ultracentrifugation, double diffu-
sion analysis in agarose gel 1 2 was performed with antisera 
to albumin, apolipoprotein A-I , A - I I , and B, and antise-
rum to total serum protein. 
CsA concentrations in total serum and fractions 
obtained after ultracentrifugation of serum were deter-
mined by radioimmunoassay.13 The measurement of 
radioactivity was performed in a LKB-Wallac liquid 
scintillation counter (model 1210 Ultra beta) with Pico-
Fluor 30 as scintillation liquid. Internal standardization 
with 3 H - H 2 0 was used for quench correction. 
Preparative Isolation of Lipoprotein 
Density Classes 
Lipoproteins were isolated from normal human plasma 
by sequential preparative ultracentrifugation according 
to Havel et al . , 1 0 using a model L5-65B ultracentrifuge 
with a rotor 60Ti (Beckman Instruments, Fullerton, C A ) . 
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Isolated lipoproteins were dialyzed exhaustively against 
0.05 mol/ l i terTris /HCl buffer, pH 7.4. 
Preparation of3H-Dihydro-CsA-Loaded 
Serum Proteins and Serum Lipoproteins 
3H-dihydro-CsA, dissolved in dimethyl sulfoxide 
(DMSO) , was rapidly injected into a vigorously stirred 
T r i s / H C l buffer (0.05 A//liter, pH 7.4) containing the 
desired protein (albumin, lipoprotein, and total serum 
proteins). The mixture was subsequently equilibrated for 
1 hr at 20-22°C by gentle shaking. The final concentra-
tion of D M S O in the protein solution did not exceed 70 
/imol/liter. The protein and CsA concentrations used are 
given under Results. 
Incubation Conditions for the CsA 
Exchange/Transfer Experiments 
Equal amounts of protein solutions previously loaded 
with 3H-dihydro-CsA and unloaded protein solutions 
were mixed and incubated under gentle shaking for 1 hr 
at 20-22°C. Subsequently, aliquots of the incubation 
mixtures were subjected to rate zonal ultracentrifugation, 
followed by analysis of 3H-dihydro-CsA distribution. 
Experimental details concerning protein and CsA concen-
trations are given under Results. 
Analytical Separation of the Major 
Lipoprotein Classes 
For the analysis of both the distribution and the 
exchange/transfer of CsA or 3H-dihydro-CsA among the 
serum lipoproteins and proteins, two different methods 
were used. 
(1) Fractionated precipitation of the major lipoprotein 
classes was performed according to the method described 
by Burstein et al . 1 4 with the following modifications.15 To 
the aliquots of serum, sodium phosphotungstate and 
magnesium chloride were added to give final concentra-
tions of 0.55 g/liter and 0.065 mol/liter, 3.0 g/liter and 
0.065 mol/liter, and 40 g/liter and 0.4 mol/liter, result-
ing in the precipitation of V L D L , V L D L plus L D L , and 
V L D L plus L D L plus H D L , respectively. The clear 
infranatants or supernatants obtained after low-speed 
centrifugation were used to measure the CsA contents. 
(2) Separation of the main lipoprotein classes by rate 
zonal ultracentrifugation was performed analogous to 
Chapman et al . 1 6 using an SW 40 Ti swinging bucket 
rotor (Beckman Instruments). Aliquots of the serum 
sample were layered on top of, or, after appropriate 
adjustment of the serum density, on the bottom of a 
discontinuous gradient. The gradients were formed from 
solutions of NaCI /KBr , sucrose or Metrizamide, varying 
in density from 1.006 g/ml to 1.25 g/ml, buffered with 
0.005 mol/liter T r i s / H C l , pH 8.0. After centrifugation 
(150,000 g at 4°C for 60 hr), fractions were collected 
from the bottom of the tubes, and the CsA content was 
measured. 
A detailed description of both procedures will be pub-
lished elsewhere.17 
RESULTS 
Relationship Between CsA Concentration 
and the Concentrations of Different Blood 
Constituents in Serum of Patients After 
Cadaver Kidney Transplantation 
Though the lipoprotein patterns of our 
renal transplant patients showed individual 
differences, the lipid and lipoprotein composi-
tion of each patient remained constant over a 
period of at least several weeks, as could be 
shown by different methods (lipid analysis, 
lipoprotein electrophoresis, and quantitative 
lipoprotein determination). After administra-
tion of a standardized dose of CsA 4 and using 
a standardized sampling procedure, no corre-
lation between the serum concentrations of 
total cholesterol, triglycerides, lipoproteins, or 
erythrocytes and the levels in serum of the 
drug could be observed. 
Distribution of CsA Among the Different 
Lipoprotein Fractions of Human Serum 
Separation by rate zonal ultracentrifuga-
tion of serum from patients receiving CsA 
revealed a close association of CsA with the 
different serum lipoprotein density classes— 
V L D L , L D L , and HDL. When the serum 
sample, after appropriate adjustment of the 
density, is layered on the bottom of the density 
gradient, approximately 30% of the recovered 
CsA is found to be associated with the non-
lipoprotein proteins, whereas 70% is found 
floating in association with HDL and L D L . In 
this case, only minute amounts of the drug 
were associated with V L D L . On the other 
hand, when the serum specimen is layered on 
top of the density gradient, the total recovered 
CsA is associated with the lipoproteins, 
including V L D L . Analogous results were 
obtained with gradients formed by potassium 
bromide, Metrizamide, or sucrose. An exam-
ple is presented in Fig. 1, (A and B). Using 
fractionated precipitation for the separation 
of the different lipoprotein classes, it could be 
demonstrated that 90%-95% of the recovered 
2 4 2 8 MRAZ ET AL. 
F r a c t . n o . 
Fig. 1. T h e in vivo and in vitro distribution of C s A among human serum lipoproteins. Samples (1.0 ml) of total 
se rum or isolated serum lipoproteins w e r e layered on top of preformed gradients, ranging in density from 1.006 to 
1.250 g / m l . For adjustment of the densi t ies, N a C I / K B r solutions w e r e used according to Havel et a l . , 1 0 buffered wi th 
0 .005 mol / l i ter T r i s / H C L , pH 8.0. After centrifugation (35,000 rpm for 60 hr at 4°C; rotor S W 40 T i , B e c k m a n 
Instruments) , f ract ions (0.5 ml) w e r e col lected from the bottom of the tubes. (A and B) Distribution pattern of C s A 
related to the lipoprotein pattern after ultracentrifugation of a patient se rum sampled 4 hr after administration of 
the drug (17 m g / k g body weight) . (O) Total protein; { • ) total cholesterol ; (A) tr iglycerides; ( • ) phospholipids (A) and 
( • ) C s A (B). I « V L D L , II - LDL , III = HDL, and IV = nonlipoprotein protein. (C and D) Distribution pattern of C s A after 
ultracentrifugation of isolated L D L , previously loaded with 3 H-d ihydro -CsA, before (C) and after (D) incubation wi th 
isolated unloaded V L D L . For further details s e e Materials and Methods and Table 1. 
CsA is associated with the lipoprotein frac-
tions (results not shown). 
Transfer/Exchange of 3H-Dihydro-CsA 
Among Different Lipoprotein Fractions 
An exchange/transfer of CsA between dif-
ferent isolated lipoprotein fractions could be 
demonstrated in vitro after incubation of lipo-
proteins previously loaded with t r i t ium-
labeled CsA and unloaded lipoproteins. Anal-
ysis of the distribution of CsA among the 
lipoprotein classes was performed by measur-
ing the radioactivity after separation of the 
different density classes by rate zonal ultra-
centrifugation (see Fig. I , C and D). A l l 
lipoprotein species investigated, that is, 
V L D L , LDL, and H D L , proved to be donor as 
well as acceptor lipoproteins. However, using 
a nonlipoprotein protein (human serum albu-
min) for the transfer/exchange experiments, 
only a transfer of 3H-dihydro-CsA to the 
lipoproteins could be observed. Some of our 
results are summarized in Table l . 
DISCUSSION 
The results presented in this article clearly 
show that the hydrophobic oligopeptide CsA 
is exclusively associated with lipoproteins in 
human serum, confirming and extending ear-
lier results. 1 8 Analogous findings were 
reported recently for different lipophilic 
drugs 1 9 , 2 0 and insecticides21 and amphiphilic 
lipids. 2 2 
Using the serum from our renal transplant 
patients, reflecting the in vivo state, a binding 
of CsA to lipoproteins could be demonstrated 
by two different separation methods, rate 
zonal ultracentrifugation (Fig. 1) and frac-
tionated precipitation. These findings could 
be confirmed in vitro (A) by selective loading 
of the lipoproteins with CsA in total serum, 
and (B) by loading of isolated lipoprotein 
C S A DISTRIBUTION AMONG LIPOPROTEINS 2429 
Tab le 1. T r a n s f e r / E x c h a n g e of 3 H-Dihydro- - C s A Among the Main Lipoprotein C l a s s e s In Vitro 
C s A Donor C s A Acceptor 
Lipoprotein/Protein Lipoprotein/Protein 
F r a c t i o n * ! Fraction* 
Distribution of 3 H-Dihydro-CsA After 
Incubation of Donor and Acceptor Lipoproteins 
VLDL LDL 
Albumin 
HDL (Nonlipoprotein Protein) 
VLDL None + 
LDL + + 
HDL + + 





Serum + + + 
Lipoprotein fractions were isolated, loaded with 3H-dihydro-CsA, and incubated with other lipoprotein fractions as described 
under Materials and Methods. 
•The following concentrations were used: VLDL, 1.0 Mmol/liter; LDL, 6.0 ^mol/liter; HDL, 3.0 ^mol/liter; Albumin 0.55 
mmol/liter. The calculation of the lipoprotein concentration was based on the data given in ref. 23 . 
•f Donor fractions contained 500 /xg/ml 3H-dihydro-CsA. Specific radioactivity: 1.25 mCi/mg. 
% Radioactivity was recovered in the density range between VLDL and LDL. 
fractions with CsA. Moreover, a bidirectional 
exchange of CsA between isolated lipoprotein 
fractions (Fig. 1 and Table 1) and a unidirec-
tional transfer of CsA from serum albumin to 
the different isolated lipoprotein classes could 
be demonstrated (Table 1). These results sug-
gest a localization of the drug at the surface of 
the lipoprotein particle. 
The question now arises whether there is a 
similar CsA exchange and/or transfer process 
between lipoproteins and cell membranes. The 
elucidation of this physiologically important 
point may help to understand, at least in part, 
the immunosuppressive effect on lymphocytes 
as well as the toxic effect on cells such as 
hepatocytes. 
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